Frontiers in Alzheimer's disease therapeutics

Jeremy G. Stone, Gemma Casadesus, Kasia Gustaw Rothenberg, Sandra L. Siedlak, Xinglong Wang, Xiongwei Zhu, George Perry, Rudy J. Castellani, Mark A. Smith

Research output: Contribution to journalReview articlepeer-review

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease which begins with insidious deterioration of higher cognition and progresses to severe dementia. Clinical symptoms typically involve impairment of memory and at least one other cognitive domain. Owing to the exponential increase in the incidence of AD with age, the aging population across the world has seen a congruous increase in AD, emphasizing the importance of disease-altering therapy. Current therapeutics on the market, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, provide symptomatic relief but do not alter progression of the disease. Therefore, progress in the areas of prevention and disease modification may be of critical interest. In this review, we summarize novel AD therapeutics that are currently being explored, and also mechanisms of action of specific drugs within the context of current knowledge of AD pathologic pathways.

Original languageEnglish (US)
Pages (from-to)9-23
Number of pages15
JournalTherapeutic Advances in Chronic Disease
Volume2
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Keywords

  • Alzheimer's disease
  • amyloid
  • antioxidants
  • cholinesterase inhibitors
  • luteinizing hormone
  • mitochondrial therapy
  • neurodegenerative drugs
  • NMDA antagonists
  • tau

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Frontiers in Alzheimer's disease therapeutics'. Together they form a unique fingerprint.

Cite this